EGFR and non-small cell lung carcinoma: Research has indicated that MTE could restore erlotinib and gefitinib efficacy in the resistant NSCLC cell line HCC827/ER, with Axl and c-Met activation in vitro and in vivo, through suppression of EGFR downstream molecules (17).